Original Article

Anti-inflammatory effects of recombinant TGF-arazyme protein on endotoxin-inflamed lung cell lines

Abstract

Background and Objectives: Pulmonary inflammation is central to the pathogenesis of various respiratory diseases, driving the need for novel therapeutics. Lipopolysaccharide (LPS) is a potent inflammatory trigger that induces proinflammatory cytokine synthesis via distinct signaling cascades. The objectives of this study were to evaluate the cytotoxic and anti-inflammatory effects of recombinant TGF-Arazyme fusion protein on LPS-stimulated human lung A549 and MRC-5 cell lines.
Materials and Methods: A gene construct fusing Arazyme with a non-mitogenic TGFα fragment was expressed, purified via Ni-NTA chromatography, and validated enzymatically. Cytotoxicity was assessed by MTT assay. Inflammatory cytokine levels (TNF-α, IL-1β, IL-6, IL-10) were quantified by RT-PCR and ELISA. Anti-inflammatory efficacy was further validated in a murine (BALB/c) air pouch model infected with E. coli.
Results: At 20 μg/mL, the chimeric protein showed no significant toxicity in MRC-5 cells but dose-dependently reduced A549 viability (p<0.01). Co-treatment with LPS and the chimeric protein significantly downregulated proinflammatory cytokines (TNF-α, IL-1β, IL-6) at both mRNA and protein levels (p<0.01, p<0.001), while increasing IL-10 (p<0.05). In the air pouch model, TGF-Arazyme reduced leukocyte counts by 48.3% (p<0.01), comparable to dexamethasone (51.2%).
Conclusion: TGF-Arazyme exhibits both anti-inflammatory and selective cytotoxic properties, positioning it as a promising candidate for inflammatory lung diseases and lung cancer.

1. Tan CL, Chan Y, Candasamy M, Chellian J, Madheswaran T, Sakthivel LP, et al. Unravelling the molecular mechanisms underlying chronic respiratory diseases for the development of novel therapeutics via in vitro experimental models. Eur J Pharmacol 2022; 919: 174821.
2. Hiemstra PS, McCray Jr PB, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J 2015; 45: 1150-1162.
3. Thacker E. Lung inflammatory responses. Vet Res 2006; 37: 469-486.
4. Kyd JM, Foxwell AR, Cripps AW. Mucosal immunity in the lung and upper airway. Vaccine 2001; 19: 2527-2533.
5. Charavaryamath C, Janardhan KS, Townsend HG, Willson P, Singh B. Multiple exposures to swine barn air induce lung inflammation and airway hyper-responsiveness. Respir Res 2005; 6: 50.
6. Donaldson K, Mills N, MacNee W, Robinson S, Newby D. Role of inflammation in cardiopulmonary health effects of PM. Toxicol Appl Pharmacol 2005; 207(2 Suppl): 483-488.
7. Hassan J, Khan AU, Bibi N, Zeb A, Ishaq S, Khan S, et al. Poncirin Protects Against LPS-induced Acute Lung Injury: Targeting MAPKs/NF-kB Signaling Using In vivo, Molecular Docking, MD Simulation and MM-PBSA/GBSA Studies. J Comput Biophys Chem 2026; 25: 1787-1814.
8. Ishii H, Hayashi S, Hogg JC, Fujii T, Goto Y, Sakamoto N, et al. Alveolar macrophage-epithelial cell interaction following exposure to atmospheric particles induces the release of mediators involved in monocyte mobilization and recruitment. Respir Res 2005; 6: 87.
9. Zhou J, Li S, Zeng Z. Dendrobine alleviates LPS-induced acute lung injury via activation of the PI3K/AKT/GSK3β pathway. J Ethnopharmacol 2025; 346: 119634.
10. Bersanetti PA, Park HY, Bae KS, Son KH, Shin DH, Hirata IY, et al. Characterization of arazyme, an exocellular metalloprotease isolated from Serratia proteamaculans culture medium. Enzyme Microb Technol 2005; 37: 574-581.
11. Rubporn A, Srisomsap C, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Svasti J, et al. Comparative proteomic analysis of lung cancer cell line and lung fibroblast cell line. Cancer Genomics Proteomics 2009; 6: 229-237.
12. Ghadaksaz A, Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nejad Satari T, Amin M. ARA-linker-TGFαL3: a novel chimera protein to target breast cancer cells. Med Oncol 2021; 38: 96.
13. Ghadaksaz A, Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nejad Satari T, Amin M. Targeting the EGFR in cancer cells by fusion protein consisting of arazyme and third loop of TGF-alpha: an in silico study. J Biomol Struct Dyn 2022;40: 11744-11757.
14. Yahyaee Z, Shahpari M, Mousavi Ghahfarrokhi SS, Shakoori M, Hashemi S, Sepahi AA, et al. Cloning and expression of recombinant arazyme with anti-inflammatory and anti-breast cancer potential. Arch Microbiol 2024; 206: 319.
15. Norouzi Z, Salimi A, Halabian R, Fahimi H. Nisin, a potent bacteriocin and anti-bacterial peptide, attenuates expression of metastatic genes in colorectal cancer cell lines. Microb Pathog 2018; 123: 183-189.
16. Jabbar Z, Irfan HM, Alamgeer, Ullah A, Mahmoud MH, Batiha GE, et al. Trans-Chalcone (1-3-diphenyl-2-propen-1-one) as a Therapeutic Candidate in Joint Inflammation via Reduction of TNF-α, IL-1β, IL-6, and IL-17 in Rodents: An In Vivo Study by RT-PCR and ELISA analysis. ACS Omega 2024; 9: 22123-22135.
17. Mursalin MH, Livingston E, Coburn PS, Miller FC, Astley R, Callegan MC. Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis. J Vis Exp 2021; 168: e61749.
18. Ghadaksaz A, Imani Fooladi AA, Mahmoodzadeh Hosseini H, Amin M, Adami Ghamsari F. Computational and in vitro targeting of HUVECs by ARA-Linker-TGFαL3 through VEGFR2. Mol Simul 2023; 50: 137-147.
19. Zahid A, Khaliq A, Nisa Mu, Maqsood Q, Hussain N, Ali SW, et al. Emerging paradigms in lung cancer treatment: recent breakthroughs and innovation. Lung cancer diagnosis and treatment: an interdisciplinary approach: Springer; 2024. p. 43-81.
20. Pan Y, Cheng J, Zhu Y, Zhang J, Fan W, Chen X. Immunological nanomaterials to combat cancer metastasis. Chem Soc Rev 2024; 53: 6399-6444.
21. Stumpo DJ, Lai WS, Blackshear PJ. Inflammation: cytokines and RNA‐based regulation. Wiley Interdiscip Rev RNA 2010; 1: 60-80.
22. Weber B, Sturm R, Henrich D, Lupu L, Rottluff K, Marzi I, et al. Diagnostic and prognostic potential of exosomal cytokines IL-6 and IL-10 in polytrauma patients. Int J Mol Sci 2023; 24: 11830.
23. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012; 13: 227-232.
24. Woitschach F, Kloss M, Kischkel S, Macháček T, Reinholdt C, Senz V, et al. Utilization of a highly adaptable murine air pouch model for minimally invasive testing of the inflammatory potential of biomaterials. Front Bioeng Biotechnol 2024; 12: 1367366.
25. Charitidis FT, Damlund DSM, Koch J. Psoriasis-like inflammation induced in an air-pouch mouse model. In Vivo 2021; 35: 1985-1997.
26. Wang Z, Zhong Z, Yang W, Li Y, Zhang K, Gong Y, et al. Traditional Chinese medicines as anticancer agents fornon-small cell lung cancer with EGFR mutations: A Review. Drug Des Devel Ther 2025; 19: 5169-5191.
Files
IssueVol 18 No 5 (2026) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v18i5.22871
Keywords
Lung inflammation Metalloproteases TGF-alpha Lipopolysaccharides A549 cells
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Zarei Koosha R, Halabian R, Fasihi-Ramandi M, Imani Fooladi AA. Anti-inflammatory effects of recombinant TGF-arazyme protein on endotoxin-inflamed lung cell lines. Iran J Microbiol. 2026;18(5):807-817.